Physician profile
Tilak Joshi
NPI 1730364522
$1,139.89
in general payments reported to CMS, 2019-2025
13 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2022: $51.08 · 2023: $29.30 · 2024: $559 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $713.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $249.98 | 2024 | |
| Amgen INC. | $128.12 | 2024-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $125.00 | 2019 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $118.73 | 2024 | |
| Pfizer INC. | $101.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $68.02 | 2022-2023 | Xarelto |
| Novo Nordisk INC | $64.19 | 2024-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $55.10 | 2024-2025 | |
| Lilly USA, LLC | $36.34 | 2024-2025 | Mounjaro |
| Smith+Nephew, INC. | $31.53 | 2024 | Oasis, Grafix Pl, Stravix Pl |
| Genentech USA, INC. | $24.17 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tilak Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.